Get started
Author

Nadav Bleich Kimelman

Observed names: N Kimelman, N. Bleich Kimelman, NADAV BLEICH KIMELMAN, Nadav Kimelman, nadav kimelman
OpenAlex ID: A5013162690
Review: Gene- and Stem Cell–Based Therapeutics for Bone Regeneration and Repair
2007 · Nadav Kimelman, Gadi Pelled, et al. · Tissue Engineering · 149
Applications of Gene Therapy and Adult Stem Cells in Bone Bioengineering
2006 · N Kimelman, G Pelled, et al. · Regenerative Medicine · 36
Mesenchymal Stem Cells
2014 · Zulma Gazit, Gadi Pelled, et al. · Elsevier eBooks · 16
Mesenchymal Stem Cells
2010 · Zulma Gazit, Gadi Pelled, et al. · Elsevier eBooks · 13
Specific Blockade of Bone Morphogenetic Protein-2/4 Induces Oligodendrogenesis and Remyelination in Demyelinating Disorders
2021 · Karin Mausner-Fainberg, Moshe Benhamou, et al. · Neurotherapeutics · 7
PDF
Real-Time Bioluminescence Functional Imaging for Monitoring Tissue Formation and Regeneration
2013 · Nadav Bleich Kimelman, Ilan Kallai, et al. · Methods in molecular biology · 4
921. In Vivo Non Viral Gene Delivery of BMP-9 Regenerates Non Union Bone Defect
2006 · Nadav Kimelman, Gadi Pelled, et al. · Molecular Therapy · 4
PDF
455. Genetically Engineered Adult Stem Cells and Hybrid Scaffolds as a Platform for Intervertebral Disc Regeneration
2006 · Nadav Kimelman, Rod J. Oskouian, et al. · Molecular Therapy · 3
PDF
Glatiramer Acetate Depot (extended-release) phase IIa study in patients with Primary Progressive Multiple Sclerosis: safety and efficacy snapshot (1911)
2021 · Shlomo Flechter, Laura Popper, et al. · Neurology · 2
Glatiramer Acetate Depot (extended-release) Phase IIa one-year study in patients with Relapsing-remitting Multiple Sclerosis: Safety, tolerability and efficacy – NEDA Analysis (P6.359)
2018 · Ariel Miller, Laura Popper, et al. · Neurology · 2
Mesenchymal Stem Cells
2012 · Zulma Gazit, Gadi Pelled, et al. · Elsevier eBooks · 2
GA Depot (Long-acting IM Injection of Glatiramer Acetate) Presents Improved Safety and Tolerability Features: Results from a Multinational, Double-blind, Placebo-controlled Phase III Study in Subjects with Relapsing Forms of Multiple Sclerosis (P8-6.018)
2024 · Aaron Miller, Laura Popper, et al. · Neurology · 1
Mesenchymal Stem Cells
2008 · Zulma Gazit, Hadi Aslan, et al. · Elsevier eBooks · 1
GA Depot (Long-acting IM Glatiramer Acetate) and its Impact on EDSS in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) (P7-19.002)
2026 · Aaron Miller, Laura Popper, et al. · Neurology
GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial
2026 · Aaron Miller, Jeffrey A Cohen, et al. · Multiple Sclerosis Journal
PDF
1689-P: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks—Pharmacokinetic Modeling and Human-Based Allometric Scaling
2025 · SHAI RUBNOV, GALINA ZATS, et al. · Diabetes
GA Depot (Long-acting IM Injection of Glatiramer Acetate) Impact on EDSS Stability in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) (P11-1.014)
2025 · Aaron Miller, Laura Popper, et al. · Neurology
Glatiramer Acetate (ga) Long-acting Injection (ga Depot) Effect in a Mouse Model of Ibd
2025 · Nadav Bleich Kimelman, Shai Rubnov, et al. · Gastroenterology
Glatiramer Acetate (ga) Long-acting Injection (ga Depot) Effect in a Mouse Model of Ibd
2025 · Nadav Bleich Kimelman, Shai Rubnov, et al. · Inflammatory Bowel Diseases
2052-LB: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks, Demonstrates Similar Efficacy and PK Profile to Daily Semaglutide Administration
2024 · SHAI RUBNOV, GALINA ZATS, et al. · Diabetes
Oral Administration of a Novel Small Molecule Blocks the BMP Canonical and the Non-canonical BMP2, BMP4, and BMP5 Signaling Pathways Ameliorates EAE Through Oligodendrogenesis Remyelination and Preservation of Axonal Integrity and Reduces Astrogenesis (P7-6.015)
2024 · Maya Golan, Moshe Benhamou, et al. · Neurology
Results of a Phase III, Multinational, Double-blind, Placebo-controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis (RMS) to Assess the Efficacy, Safety, and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four Weeks (P6-3.014)
2023 · Aaron Miller, Laura Popper, et al. · Neurology
Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Primary Progressive Multiple Sclerosis: Safety and Efficacy Snapshot (P7-4.001)
2022 · Shlomo Flechter, Laura Popper, et al. · Neurology
Five Years Analysis of anti-Glatiramer Acetate (GA) Antibodies in Patients with Relapsing Remitting Multiple Sclerosis Treated with GA Depot (P5-4.010)
2022 · Shlomo Flechter, Ariel Miller, et al. · Neurology
Specific Blockade of Bone Morphogenetic Protein-2/4 induces Oligodendrogenesis and Remyelination in Demyelinating Disorders (2042)
2021 · Karin Fainberg-Mausner, Moshe Benhamou, et al. · Neurology
Works count: 34
Citation count: 240
H-index: 5
I10-index: 4
Year
Topic
Type